Sentiments around Neothetics Inc. (NASDAQ:NEOT) about to change?

1003

Shares of Neothetics, Inc. (NASDAQ:NEOT) last traded at $2.01. The firm’s performance so far in this year is 79.46%. The 200-day simple moving average is 43.05%. It is considered a key indicator by market analysts and traders for determining the long-term trend. The price mark in a market that coincides with it is recognized as a key support when price moves above the 200-day SMA or resistance when stock price is below this level.

As per recent filings, Neothetics, Inc. (NASDAQ:NEOT) has an insider ownership of 54.08%.

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The Company is focused on localized fat reduction and body contouring. Its lead product candidate, LIPO-202, is for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company is also developing LIPO-102 for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye. Neothetics, Inc. is headquartered in San Diego, California.

Neothetics, Inc. (NASDAQ:NEOT) has been storming Wall Street with promising press release. Recently, the firm reported that according to the March 2017 analysis commissioned by RetailMeNot and performed by Forrester Consulting, the firm’s mobile marketing solutions result in a 3-year, risk-adjusted ROI of 4.3x.

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The Exponential Moving Average is a tool same as a simple moving average, with the only difference being a weighting factor used by EMA that exponentially declines from the recent data point. EMA analysis checks the averages for different period, including short term that is 5 days and 13 days, intermediate term for 20 days and long term of 50 days EMA. The bullish signals are received when they trade above trailing EMAs and below the prevailing price and vice versa. EMA signals include crossovers and EMA convergences Currently, the 5 day EMA 2.29 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 2.01 is lower than current trading price depicting a bullish signal..

The relative strength index can be marked as a momentum oscillator that is able to read the velocity and magnitude of equity price changes. The current RSI is 43.37 suggesting a bearish price action.

Neothetics, Inc. (NASDAQ:NEOT) is all set to post its earnings on May 11/b. As per Zack’s analyst ratings, Neothetics, Inc. (NASDAQ:NEOT) presently has an average brokerage rating of . On a scale of 1 – 5, a rating of 2 or 1 would indicate a buy, and a 4 or 5 rating would signify a sell while a rating of 3 indicates a hold. The consensus target price on (NASDAQ:NEOT) is $ with a high of $ and a low of $.

As such, while we consider Neothetics, Inc. (NASDAQ:NEOT) represents a convincing growth story exposed to different attractive markets, it would be enticing to see what it brings for long-term investors.

Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.